Audentes Therapeutics Inc (BOLD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Audentes Therapeutics Inc (BOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8283
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and life-threatening rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment of Pompe disease; AT342, for the treatment of crigler-najjar syndrome; and AT307, for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Audentes offers viral vectors for gene therapy most frequently and track record off adeno-associated virus vector (AAV) in non-pathogenic product, among others. The company has collaboration with various patient, research and medical communities to advance its product candidates. Audentes is headquartered in San Francisco, California, the US.

Audentes Therapeutics Inc (BOLD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Partnerships 21
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Licensing Agreements 23
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 24
Audentes Therapeutics Amends its Licensing Agreement with University of Florida Research Foundation 26
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 28
Equity Offering 29
Audentes Therapeutics Prices Public Offering of Shares for USD150.8 Million 29
Audentes Therapeutics Raises USD231 Million in Public Offering of Shares 31
Audentes Therapeutics to Raise up to USD75 Million in Public Offering of Shares 33
Audentes Therapeutics Raises USD86.3 Million in Public Offering of Shares 34
Audentes Therapeutics Raises USD75 Million in IPO 36
Acquisition 37
Audentes Therapeutics Acquires Cardiogen Sciences 37
Audentes Therapeutics Inc – Key Competitors 38
Audentes Therapeutics Inc – Key Employees 39
Audentes Therapeutics Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 07, 2018: Audentes Therapeutics Reports Second Quarter 2018 Financial Results 41
May 09, 2018: Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 43
Mar 08, 2018: Audentes Therapeutics Announces Fourth Quarter 2017 And Full Year Financial Results 45
Nov 14, 2017: Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 46
Aug 10, 2017: Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 47
May 11, 2017: Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 49
Mar 09, 2017: Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 51
Jan 09, 2017: Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance 54
Corporate Communications 56
Oct 03, 2018: Audentes Therapeutics announces co-founder and chief executive Officer Matthew R. Patterson appointed chairman of the alliance for regenerative medicine 56
May 08, 2018: Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer 57
Dec 13, 2017: Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors 58
Jun 13, 2017: Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors 59
May 08, 2017: Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer 60
Product News 61
04/30/2018: Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 24
Audentes Therapeutics Amends its Licensing Agreement with University of Florida Research Foundation 26
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 28
Audentes Therapeutics Prices Public Offering of Shares for USD150.8 Million 29
Audentes Therapeutics Raises USD231 Million in Public Offering of Shares 31
Audentes Therapeutics to Raise up to USD75 Million in Public Offering of Shares 33
Audentes Therapeutics Raises USD86.3 Million in Public Offering of Shares 34
Audentes Therapeutics Raises USD75 Million in IPO 36
Audentes Therapeutics Acquires Cardiogen Sciences 37
Audentes Therapeutics Inc, Key Competitors 38
Audentes Therapeutics Inc, Key Employees 39
Audentes Therapeutics Inc, Subsidiaries 40

List of Figures
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Audentes Therapeutics Inc (BOLD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Parkland Fuel Corp (PKI):企業の財務・戦略的SWOT分析
    Parkland Fuel Corp (PKI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Kaiser Foundation Health Plan of Washington:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan of Washington - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Chugach Electric Association, Inc.:企業の発電所・SWOT分析2018
    Chugach Electric Association, Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information o …
  • adidas AG (ADS):企業の財務・戦略的SWOT分析
    adidas AG (ADS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Natural Alternatives International Inc (NAII):企業の財務・戦略的SWOT分析
    Summary Natural Alternatives International Inc (NAI) is a formulator and manufacturer of customized nutritional supplements. The company manufactures and distributes the only patented beta-alanine supplement on the market. It offers services such as science-based product formulation, raw material ac …
  • Therabron Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Therabron Therapeutics Inc (Therabron), formerly Clarassance Inc is a clinical-stage biopharmaceutical company that develops drugs based on secretoglobin family of proteins. The company’s lead biopharmaceutical candidate includes CG100, CG201, CG367, CG459 and CG1011. Its CC10 protein candid …
  • Bioderm Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bioderm Inc (Bioderm) is a medical equipment company that manufactures designs, and markets hydrocolloid products. The company manufactures hydrocolloid products for urinary management, securement, infection control, and skin protection. Its products include cathgrip, bioplus+, freederm, men …
  • Avivagen Inc (VIV):企業の財務・戦略的SWOT分析
    Summary Avivagen Inc (Avivagen), formerly Chemaphor Inc is a biotechnology company that provides drug development and animal healthcare products. The company develops science-based, natural health products for animals. It operates through divisions including companion animal health, food animal heal …
  • Philips Healthcare-製薬・医療分野:企業M&A・提携分析
    Summary Philips Healthcare, formerly Philips Medical Systems, undertakes the manufacture and distribution of diagnostic imaging systems, healthcare information technology solutions, patient monitoring and cardiac devices. Philips Healthcare is a division of Royal Philips Electronics of the Netherlan …
  • ABC Supply Co. Inc.:企業のM&A・事業提携・投資動向
    ABC Supply Co. Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ABC Supply Co. Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • PGNiG SA (PGN):石油・ガス:M&Aディール及び事業提携情報
    Summary PGNiG SA (PGNiG) is a vertically integrated gas company. The company’s activities include domestic natural gas and crude oil production, development of natural gas and crude oil fields in Poland and abroad, provision of geological, geophysical and exploration services in Poland and abroad, i …
  • True Corporation Public Company Limited:企業の戦略・SWOT・財務情報
    True Corporation Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary True Corporation Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • MedEquities Realty Trust, Inc. (MRT):企業の財務・戦略的SWOT分析
    MedEquities Realty Trust, Inc. (MRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Shire Plc (SHP):製薬・医療:M&Aディール及び事業提携情報
    Summary Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to treat patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas …
  • Ampio Pharmaceuticals Inc (AMPE):企業の財務・戦略的SWOT分析
    Summary Ampio Pharmaceuticals Inc (Ampio) formerly Chay Enterprises Inc, operates as a bio pharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory co …
  • Polaris Industries Inc.:企業の戦略・SWOT・財務情報
    Polaris Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary Polaris Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Linde AG (LIN)-製薬・医療分野:企業M&A・提携分析
    Summary Linde AG (Linde) is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. Linde offers a wide range of compressed and liquefied gases, and chemicals, and offers facili …
  • Alkermes Plc (ALKS)-製薬・医療分野:企業M&A・提携分析
    Summary Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company’s proprietary products include Aristada, an extended-release intramuscular injectable suspen …
  • GridEdge Networks Inc:企業の戦略的SWOT分析
    GridEdge Networks Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • VPK Packaging Group NV:企業の戦略・SWOT・財務情報
    VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report Summary VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆